title: Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.
abstract: OBJECTIVE
  Aspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). However, its use is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk for haemolytic anaemia). We report the management of 2 patients with class II G6PD deficiency and non-ST-segment elevation ACS (NSTE-ACS).
  
  
  METHODS
  The two patients were safely and efficiently treated with dual antiplatelet treatment (DAPT, aspirin plus ticagrelor) and PCI using new-generation drug-eluting stent (DES) despite G6PD deficiency.
  
  
  CONCLUSIONS
  NSTE-ACS management with DAPT and DES is probably safe and effective in class II G6PD-deficient patients.
authors: Cardiology Department, 'KAT' General Hospital of Attica, 14561, Athens, Greece.
authors: N V
authors: NV
authors: Kafkas
authors: C I
authors: CI
authors: Liakos
authors: A G
authors: AG
authors: Mouzarou
mesh_terms: D054058:Acute Coronary Syndrome / Q000503:physiopathology / Q000628:therapy*; D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000077486:Ticagrelor
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077486:Ticagrelor; D000241:Adenosine; D001241:Aspirin
keywords: Glucose-6-phosphate dehydrogenase (G6PD) deficiency; acetylsalicylic acid; acute coronary syndromes; angioplasty; aspirin; favism